CAPS Medical

CAPS Medical is a biotechnology company dedicated to developing innovative cancer treatment solutions through advanced technology. Their flagship product, PlasmaSure™, targets cancer cells in solid tumors while preserving healthy tissue, offering a potential new avenue for cancer care. Founded in 2018 and headquartered in Netanya, Israel, CAPS Medical focuses on the development of advanced cancer treatment technologies. The company is led by CEO Ilan Uchitel and has undergone a significant funding round, raising USD 3.

5 mn in Series A funding on July 29, 2020, co-led by Israel Investment Fund Group and Chasing Value Asset Management, among others. The business has not noted any significant pivots or changes in strategy since its inception. CAPS Medical specializes in delivering innovative cancer treatment solutions, primarily through its flagship product, PlasmaSure™. This device utilizes Non-thermal Atmospheric Plasma technology to perform minimally invasive procedures aimed at selectively targeting and destroying cancer cells in solid tumors while preserving surrounding healthy tissue.

The technology addresses significant challenges in delivering treatment directly to internal organs, providing a promising alternative for patients with various cancer types, including lung, liver, breast, gastrointestinal, bladder, and prostate cancers. CAPS Medical’s offerings are designed to serve a wide range of healthcare providers, including hospitals and specialized cancer treatment centers, primarily in North America and Europe. The solutions are intended for investigational device use and are currently not cleared for marketing in the USA and other regions. CAPS Medical is positioned within a substantial market opportunity valued at approximately USD 100 bn, driven by the urgent need for effective cancer treatments given the 9.

5 million annual cancer-related deaths globally. Revenue generation is anticipated through partnerships with healthcare facilities that utilize the PlasmaSure™ device in clinical settings. The transaction structure is expected to involve direct sales to hospitals and treatment centers, where CAPS Medical provides the equipment and possibly ongoing support or consumables associated with the procedures. Specific pricing details for the PlasmaSure™ device and related services are not disclosed, but the transactional framework likely involves direct agreements with healthcare providers for the deployment of their technology in patient care.

The recent Series A funding of USD 3. 5 mn raised on July 29, 2020, will support CAPS Medical's strategic initiatives for future growth. The company aims to expand its market presence by targeting healthcare providers in North America and Europe for the deployment of its PlasmaSure™ device. Additionally, CAPS Medical is focused on advancing new product designs to enhance its treatment offerings, although specific release dates are not mentioned.